Clinical Design and Objectives

The Phase 2 MyroMatch trial targets patients with high‑risk acute myeloid leukemia (AML) and compares standard therapy with four experimental regimens. Enrollment began on September 25, 2024 and is ongoing. The primary endpoints are complete remission rate and progression‑free survival; the anticipated completion date has not been specified.

Mechanisms of the Experimental Regimens

The investigational arms combine cyclophosphamide (CyTarabine), daunorubicin liposome, Benetuxaf (Beneclex), and azacitidine, among others. Benetuxaf blocks the BCL‑2 protein to promote cancer cell apoptosis, while azacitidine inhibits DNA methylation to support normal hematopoiesis. This combination may enhance AML eradication efficiency compared with conventional cyclophosphamide‑daunorubicin.

Unmet Medical Need in the Patient Population

High‑risk AML exhibits genetic mutations and treatment resistance, resulting in low success rates with existing therapies. Patients who fail to respond to initial treatment face a high risk of relapse, creating an urgent need for new therapeutic options. This trial aims to validate a strategy that overcomes resistance and improves survival prospects.

Potential Market and Industry Impact

If the experimental regimens demonstrate superiority over standard care, a combination therapy containing Benetuxaf and azacitidine could become a first‑line option for AML. This would provide new revenue growth drivers for the drug manufacturers and biotech firms, potentially reshaping the competitive landscape of the high‑risk AML market. Moreover, clinical success of liposome‑based drug delivery could catalyze adoption across other hematologic malignancies.